SCRI-CAR19x22v2

SCRI-CAR19x22v2 is an investigational **autologous dual-target CAR-T cell therapy** developed at Seattle Children's Research Institute for relapsed or refractory B-cell acute lymphoblastic leukemia, particularly in pediatric and young adult patients. The product consists of patient-derived T cells separately transduced with two lentiviral vectors encoding a **CD19-directed** or **CD22-directed** chimeric antigen receptor, each using **4-1BB costimulatory signaling**, to generate antileukemic activity against leukemic blasts expressing either antigen. It was engineered as an improved version of SCRI-CAR19x22v1 after the earlier construct showed dominant CD19 CAR engraftment and insufficient eradication of CD19-negative, CD22-positive escape disease. The therapy has been evaluated in the phase 1 PLAT-05 study and is a cell-based biologic intended to reduce antigen escape by simultaneously targeting two B-lineage surface antigens.

Other names

CD19/CD22 bispecific CAR T-cell product v2dual-transduced CD19/CD22 CAR T-cell therapy